LUND, Sweden, Oct. 29, 2021 /PRNewswire/ -- Immunovia AB (publ)
("Immunovia"), a diagnostic company that develops and sells highly
accurate blood tests for the early detection of cancer, today
announced that Thomas King, MD, PhD,
Medical Director of Immunovia, Inc. was invited to present to the
U.S. National Cancer Institute (NCI) Pancreatic Cancer Detection
Consortium (PCDC) as a keynote speaker at their upcoming Steering
Committee Meeting, taking place virtually on December 13-14, 2021.
Dr. Thomas King's keynote
presentation will focus on Immunovia's recent progress on the early
detection of pancreatic cancer and the study results for the
IMMray™ PanCan-d test. Immunovia's IMMray™ PanCan-d test is the
world's first blood test dedicated to early detection of pancreatic
cancer. It is available as a laboratory developed test in the US
exclusively through Immunovia, Inc..
"We are very excited to participate in this NCI sponsored
program since we feel that robust biomarkers such as those
contained in the IMMray™ PanCan-d test represent the best current
opportunity to impact the survival of PDAC patients by detecting
tumors at an early stage when they are potentially resectable,"
said Dr. Thomas King.
The main objective of the PCDC is to "develop and test new
molecular and imaging biomarkers to improve the detection of
early-stage pancreatic ductal adenocarcinoma (PDAC) and its
precursor lesions and identify individuals who are at high risk of
developing PDAC and are candidates for early intervention."
There are eight PCDC teams focused on this objective, with
Principal Investigators from leading pancreatic cancer academic
centers around the US.
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Tel: +46 73 376 76 64
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer based on Immunovia's proprietary test platform
called IMMray™. Tests are based on antibody biomarker
microarray analysis using advanced machine-learning and
bioinformatics to single-out a set of relevant biomarkers that
indicate a certain disease. Thus, forming a unique "disease
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com. The European
launch plan will be communicated during the second half of
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
The following files are available for download:
SOURCE Immunovia AB